anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Padsevonil (PSL) is a rationally designed anti-seizure medication (ASM) which has overlapping mechanisms of action with the two most common ASMs used for neonatal seizures, phenobarbital (PB) and levetiracetam (LEV). Here we evaluated the anti-seizure properties of PSL across the neonatal and adolescent period in rats in the pentlyenetetrazole (PTZ) induced seizures model.
METHODS: Postnatal day (P)7, P14 and P21 Sprague-Dawley rat pups were pre-treated with PSL (1-30 mg/kg), and assessed for seizure latency and severity 30 min later following injection of PTZ. A separate cohort of P7 pups were treated with neonatal ASMs and euthanized 24 h later (on P8) to assess induction of cell death, a feature common to many ASMs when given to P7 rodents. This effect has been extensively reported with PB, but not with LEV. Cell death was assessed by PathoGreen staining.
RESULTS: PSL suppressed PTZ-evoked seizures across multiple age groups, particularly at higher doses, without producing increased cell death compared to vehicle. The effects of PSL were particularly notable at suppressing tonic-clonic seizure manifestations (82% of P7 and 100% of P14 and P21 animals were protected from tonic-clonic seizures with the 30 mg/kg dose).
CONCLUSIONS: PSL displayed dose-dependent anti-seizure effects in immature rodents in the PTZ model of seizures in immature rats. While many ASMs, including PB, induce cell death in neonatal rats, PSL does not. This suggests that PSL may offer therapeutic benefit and a favorable safety profile for the treatment of neonatal seizures.
The invention relates to a preparation method of a colistin sulfate premix, successively comprising the following steps: fermentation, pretreatment of a fermentation broth, filtration, ultrafiltration, first concentration, secondary concentration, and drying. The technology is simple; yield is high; and cost is low. The whole technological process is a physical separation process, and no organic solvent is adopted. Thus, pollutants are greatly reduced. In addition, energy conservation and consumption reduction are realized. The prepared colistin sulfate premix has stable quality, good storage stability and good using effect.
OBJECTIVE: To study the prevalence of chronic fatigue syndrome (CFS) and association of CFS with other clinical and neuropsychological manifestations of Parkinson's disease (PD) as well as with serum inflammatory markers and genetic polymorphisms.
MATERIAL AND METHODS: The study included 533 patients with PD. All patients underwent clinical, neurological examination and neuropsychological testing using validated questionnaires: MoCA test, HADS, BDI-II, the Fatigue Severity Scale (FSS). Serum concentrations of inflammatory markers (slCAM-1, sVCAM-1, NCAM, CCL5, PAI-1 and MPO) were assessed in 144 patients using xMAP technology. A case-control study of CCL5 (rs2107538) and PAI-1 (rs2227631) gene polymorphisms was performed in connection with PD development and in groups differing in the presence/absence of CFS in PD. In addition, the relationship of these polymorphisms with variability in the levels of the corresponding proteins in the blood serum of patients was studied. Genotyping of CCL5 (rs2107538) and PAI-1 (rs2227631) polymorphisms was performed using real-time PCR with TaqMan probes.
RESULTS: CFS is common in 66.7% of patients in the PD group. In addition, non-motor symptoms (emotional-affective, cognitive, autonomic disorders and pain) were more common in patients with CFS. A strong correlation has been established between the severity of CFS assessed with FSS and serum concentrations of CCL5, sVCAM-1, NCAM and slCAM-1. In newly diagnosed patients with PD who were not taking antiparkinsonian drugs at the time of the study and had CFS, higher correlations were noted between inflammatory markers and the severity of CFS manifestations. When comparing the distribution of genotypes and alleles of CCL5 (rs2107538) and PAI-1 (rs2227631) polymorphisms, some differences were found between the groups of patients with PD and controls (p<0.05). However, these polymorphisms did not affect the variability of serum protein levels CCL5 and PAI-1, respectively, nor did they affect the development of CFS in patients with PD.
CONCLUSION: CFS is common in PD, and patients with PD and CFS are characterized by elevated levels of serum markers CCL5, sVCAM-1, slCAM-1 and NCAM, suggesting the importance of the inflammatory component in the development of neurodegenerative disease. In addition, the clinical course of PD in patients with CFS is aggravated by other non-motor manifestations, including emotional-affective, cognitive, autonomic disorders and pain. These results highlight the potential contribution of an inflammatory component to the development of fatigue associated with PD, starting from the earliest clinical stages of the disease.
Peritoneal fibrosis (PF) is a primary reason for discontinuing peritoneal dialysis, which involves characteristic changes of peritoneal mesothelial cells (PMCs). We previously reported preventive effects of implanting human epithelial-like PMCs (P-Epi) for mouse PF caused by mechanical peritoneum scrapings. In the present study, we analysed the preventive effects of culture supernatant of P-Epi in PF. Concentrated culture supernatant of P-Epi or human fibroblast-like PMCs (P-Fibro) or vehicles was injected into nude mice that had undergone mechanical scraping of the parietal and visceral peritoneum, and thickness and amount of adhesions were analysed. Although increased peritoneal adhesions and peritoneum thickening were observed in the vehicle-injected positive control group compared to the sham operation group, fewer number of adhesions and less thickness were observed in the mice treated with culture supernatant of P-Epi, but not P-Fibro, compared to the vehicle-injected positive controls. Immunofluorescent analysis revealed that the expression of extracellular matrix, type I collagen and fibronectin, was lower in the mice treated with culture supernatant of P-Epi than in the vehicle-injected positive controls. In addition, exosomes from P-Epi significantly reduced transforming growth factor-β (TGF-β)-induced expressions of type I collagen and fibronectin in 3T3 fibroblast cells. Collectively, culture supernatant of P-Epi has preventive effects on PF, thus cell therapy is not necessarily required. Further exploration of substances secreted by P-Epi and their protective mechanisms could lead to the development of therapeutic strategies to limit PF.
Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
Major depression is characterized by an episodic course with symptom manifestations differing across episodes. Previous work has found that symptom presentation differs across age. However, studies of symptom presentation have largely focused on symptoms in individual episodes, requiring further investigation of longitudinal symptom change. This study explored the impact of the initial age of onset, the number of episodes, and age of onset of each episode on individual depressive symptoms, while accounting for episode severity. We used data from the Oregon Adolescent Depression Project (N = 629) examining participants with at least one major depressive episode, assessed by diagnostic interview, across a 15-year follow-up. Multilevel logistic regression models revealed that approximately 20-25% of the main effects were significant and some were qualified by cross-level interactions. However, only a few associations remained robust after correcting for multiple comparisons. Specifically, older initial age of onset was associated with fatigue, younger initial age of onset for the first episode was associated with suicidal ideation, and a lower episode number was associated with weight loss. These findings highlight potential initial age of onset and scar effects influencing symptom manifestation, but require replication.
The present invention discloses an orthodontic measurement analysis system, which adopts the VC++ and MS SQL Server database technology and uses a C/S structure. The system includes a hardware system which consists of an image collecting equipment, a plurality of clients, an application server and a database and a software system which consists of a case history management system, a dental cast measurement system and a data analyzing system. The present invention has the beneficial technical effects that the dental cast measurement analyzing data are accurate and safe. The predicated results can be assisted to the doctor diagnosis. The statistical data provide the basis for later case studies. The virtual orthodontic results provide the safe guarantees for patients. The system has the advantages of simple operation and low cost, which is applied to the measurement and the analysis of the orthodontic dental cast.
BACKGROUND: The Caspase activation and recruitment domain 8 (CARD8) protein is a component of innate immunity as a negative regulator of NF- ĸB, and has been associated with regulation of proteins involved in inflammation. Expression of CARD8 mRNA and protein has been identified in human atherosclerotic lesions, and the truncated T30A variant (rs2043211) of CARD8 has been associated with lower C-reactive (CRP) and MCP-1 levels in myocardial infarction patients. The present study examines the role of a genetic variation in the CARD8 gene in relation to a selection of markers of inflammation.
METHODS: In a cross-sectional study of young healthy individuals (18.0-25.9 yrs, n = 744) the association between the rs2043211 variant in the CARD8 gene and protein markers of inflammation was assessed. Genotyping of the CARD8 C10X (rs2043211) polymorphism was performed with TaqMan real time PCR on DNA from blood samples. Protein levels were studied via Olink inflammation panel ( https://olink.com/ ). Using linear models, we analyzed men and two groups of women with and without estrogen containing contraceptives separately, due to previous findings indicating differences between estrogen users and non-estrogen using women. Genotypes were analyzed by additive, recessive and dominant models.
RESULTS: The minor (A) allele of the rs2043211 polymorphism in the CARD8 gene was associated with lower levels of CCL20 and IL-6 in men (CCL20, Additive model: p = 0.023; Dominant model: p = 0.016. IL-6, Additive model: p = 0.042; Dominant model: p = 0.039). The associations remained significant also after adjustment for age and potential intermediate variables.
CONCLUSIONS: Our data indicate that CARD8 may be involved in the regulation of CCL20 and IL-6 in men. No such association was observed in women. These findings strengthen and support previous in vitro data on IL-6 and CCL20 and highlight the importance of CARD8 as a factor in the regulation of inflammatory proteins. The reason to the difference between sexes is however not clear, and the influence of estrogen as a possible factor important for the inflammatory response needs to be further explored.
Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
The invention discloses a traditional Chinese medicine composition for resisting a respiratory syncytial virus. The composition is prepared from the following bulk drugs: Saussurea epilobioides, Dracocephalum tanguticum, licorice root, root of large-flowered skullcap and patrinia herb. The invention also discloses a preparation method for the composition. The preparation method comprises a step of mixing alcohol extract of Saussurea epilobioides and Dracocephalum tanguticum with aqueous extract of the licorice root, root of large-flowered skullcap and patrinia herb and a step of preparing a dosage form frequently used in pharmacology. The traditional Chinese medicine composition has strong activity in resisting the respiratory syncytial virus. Results of toxicity test show that the traditional Chinese medicine composition provided by the invention is small in an effective dosage, low in toxicity, free of adverse reaction, safer in usage, low in cost, employs easily available raw materials, can be sustainably developed and has wide application prospects.
PCT No. PCT/EP84/00049 Sec. 371 Date Oct. 9, 1984 Sec. 102(e) Date Oct. 9, 1984 PCT Filed Feb. 27, 1984 PCT Pub. No. WO84/03699 PCT Pub. Date Sep. 27, 1984.Novel 3-amino-tetrahydro-1,3-thiazine-2,4-diones as well as skin treating compositions on the basis of a physiologically compatible carrier and customary additions containing these novel 3-amino-tetrahydro-1,3-thiazin-2,4-dione derivatives as active ingredients for thickening the epidermis. The skin treating compositions are applied 1-2 times daily on the skin for about 3 to 4 weeks. Due to the thickening of the epidermis they cause a strengthening of the skin protection, in particular against sun rays, cold and the contact with harmful environmental substances of all kinds. Moreover, the skin treating compositions are suitable for prophylactically fighting the so-called ageing of skin.
Patients in this group receive treatment with exogenous nitric oxide (NO) via the CPB machine. After CPB, NO is administered through the inspiratory limb of the anesthetic or ventilator circuit and then via the mechanical ventilator in the ICU. Once patients are extubated, they will breathe NO through a facemask or nasal cannula. NO administration begins at the start of CPB and continues for 12 hours post-operation.
Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
An electronic logbook and method are provided for storing and displaying data for use by a diabetes patient. The electronic logbook includes memory for storing patient and program data, a user input device or keyboard for entering a plurality of user input selections and a processor device coupled to the memory and the user input device for generating at least one menu screen. The menu screen includes a plurality of predetermined indicia corresponding to a subplurality of the of user input selections. Responsive to an identified user input selection, the stored patient data is selectively accessed for generating a desired report. A display device is operatively driven by the processor device for displaying the generated report. <IMAGE>
Heat therapy (HT) is an emerging non-invasive approach that has been shown to enhance vascular function of the leg in old individuals. The objective of this study is to establish evidence to support the validity of HT in improving walking tolerance on PAD patents.

Subjects will complete baseline assessments for eligibility, including medical history and ankle-brachial measurement. Eligible participants will be asked to report to the laboratory on 4 different occasions. The purpose of visits 1 and 2 The central hypothesis of this study, based on preliminary data, is that exposure to HT will enhance the oxygenation of calf muscles during exercise and as a result, the onset of pain will be delayed and walking performance will be enhanced. is to familiarize the participants with the treadmill walking test and assess the test-retest reliability of maximal walking time determination. On visits 3 and 4 participants will receive either heat treatment or a control treatment for 80 min prior to undergoing a symptom-limited incremental test on the treadmill.
Patients participating suffered from primary headaches (migraine, cluster, and tension headache) and occipital neuralgia were enrolled in the study. They have all received in the past the standard systemic pharmacotherapy prophylaxis for headache management (with topiramate or amitriptylline) as well as tryptanes for rescue treatment, and were scheduled for a diagnostic nerve block of the occipital nerves in cases of intractable pain. Inclusion criteria included: not adequate response to systemic pharmacotherapy, pain over crises of \>4/10, occipital tenderness bilaterally or unilaterally, and days with headache of more than 10/month. Exclusion criteria were age\<18 years old, pregnancy or lactation, presence of cardiac pacemaker, previous therapy with PRF, severe psychiatric disorder and patient refusal. In cases of a positive response to the diagnostic nerve block with local anesthetic, with \>50% pain relief they were scheduled for pulsed radiofrequency of GON and LON bilaterally.

Primary outcome measure was the days with headache per month, before and after treatment. In addition, pain during headache crisis (with Visual Analogue Scale, VAS, 0-10), the analgesic consumption (number per month) and the quality of life (measured with EQ6D) were studied. All measurements were performed before treatment, as well as after 1, 3, 6, and 12 months. All patients completed the Brief Pain Inventory questionnaire in Greek language and signed an informed consent prior treatment. All measurements were accomplished by an independed (blinded) researcher of the pain unit. All complications and side effects were also recorded.
GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
<P>PROBLEM TO BE SOLVED: To provide a polypeptide which inhibits the binding of fibronectin to GPIIb-IIIa.  <P>SOLUTION: Novel polypeptides derived from human fibronectin, and fusion proteins containing those peptide sequences are described which define a receptor binding site on fibronectin that binds to the platelet receptor glycoprotein GPIIb-IIIa expressed by cells. The receptor binding site of human fibronectin includes at least fibronectin amino acid residues 1410-1436. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors preparing the fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
PURPOSE:A Bu-2695 antibiotic substance complex obtained by cultivating a strain of Streptomyces hygroscopicus having the identified characteristic of ATCC No. 39150 in an aqueous nutrient culture medium under aerobic conditions by the submerged culture method. CONSTITUTION:A strain of Streptomyces hygroscopicus No. J296-21 having the identified characteristic of ATCC No. 39150 is inoculated into an aqueous nutrient culture medium containing an assimilable carbon source, nitrogen source, nutrient inorganic salt and a very small amount of a heavy metal salt and cultivated aerobically at 5-10 pH and 20-43 deg.C for 4-7 days by the submerged culture method to produce a Bu-2659 complex consisting of Bu-2659A-E. The resultant complex is then separated into the components Bu-2659A, B, C, D and E if necessary by the chromatographic means.
It is a 32-question scale developed based on the Conceptual Framework of the European Health Literacy Scale Study. The Turkish Health Literacy Scale (TSOY-32) was developed to assess health literacy in literate people over the age of fifteen. Unlike the original scale, the scale consists of eight components including two dimensions (treatment and service, disease prevention and health promotion) and four processes (accessing health-related information, understanding health-related information, evaluating health-related information, and using/applying health-related information). The overall internal consistency coefficient of the scale was 0.92. The Cronbach's alpha coefficient of the first dimension 'Treatment and Service Subdimension' is 0.88. The Cronbach's alpha coefficient of the second dimension 'Disease Prevention and Health Promotion Dimension' is 0.86. Permission to use the scale was obtained.
Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
In an aging society with common lifestyle-associated health issues such as obesity and diabetes, chronic wounds pose a frequent challenge that physicians face in everyday clinical practice. Therefore, nonhealing wounds have attracted much scientific attention. Several in vitro and in vivo models have been introduced to deepen our understanding of chronic wound pathogenesis and amplify therapeutic strategies. Understanding how wounds become chronic will provide insights to reverse or avoid chronicity. Although choosing a suitable model is of utmost importance to receive valuable outcomes, an ideal in vivo model capturing the complexity of chronic wounds is still missing and remains a translational challenge. This review discusses the most relevant mammalian models for wound healing studies and provides guidance on how to implement the hallmarks of chronic wounds. It highlights the benefits and pitfalls of established models and maps out future avenues for research.
The invention discloses a supercritical carbon dioxide extracted purple ginger volatile oil clathrate. The main components of purple ginger volatile oil are 2-thiophenecarboxaldehyde, 4-terpenol, beta-sesquiphellandrene, and curcumin. Volatile oil is included in the cavity of beta-cyclodextrin. The preparation method comprises the following steps: preparing a water solution of beta-cyclodextrin, preparing a solution of purple ginger volatile oil, dropwise adding the purple ginger volatile oil solution into the beta-cyclodextrin water solution, stirring the solution by a magnetic stirring apparatus, carrying out clathration for 1 to 3 hours at a temperature of 35 to 55 DEG C, storing the system for 24 hours at a temperature of 4 DEG C, and performing suction filtration, washing and drying to obtain white powdery purple ginger clathrate. The preparation method has the advantages of reasonable design, good technological repeatability, high product quality, high yield of clathrate, and high utilization rate of clathrate volatile oil. The dosage form and application range of purple ginger volatile oil are both enlarged through the clathrate, and the medical application of purple ginger a traditional Dai drug is also enlarged.